Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Total Debt (2016 - 2025)

Sanofi's Total Debt history spans 11 years, with the latest figure at $16.6 billion for Q4 2025.

  • For Q4 2025, Total Debt fell 3.0% year-over-year to $16.6 billion; the TTM value through Dec 2025 reached $16.6 billion, down 3.0%, while the annual FY2025 figure was $16.1 billion, 7.04% down from the prior year.
  • Total Debt for Q4 2025 was $16.6 billion at Sanofi, down from $17.1 billion in the prior quarter.
  • Across five years, Total Debt topped out at $23.2 billion in Q4 2021 and bottomed at $16.6 billion in Q4 2025.
  • The 5-year median for Total Debt is $17.6 billion (2023), against an average of $18.8 billion.
  • The largest annual shift saw Total Debt decreased 16.42% in 2022 before it decreased 3.0% in 2025.
  • A 5-year view of Total Debt shows it stood at $23.2 billion in 2021, then fell by 16.42% to $19.4 billion in 2022, then dropped by 9.17% to $17.6 billion in 2023, then fell by 3.06% to $17.1 billion in 2024, then dropped by 3.0% to $16.6 billion in 2025.
  • Per Business Quant, the three most recent readings for SNY's Total Debt are $16.6 billion (Q4 2025), $17.1 billion (Q4 2024), and $17.6 billion (Q4 2023).